Histopathologic And Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations

By sjmartinez • December 9, 2024

Seo YJ, Huston-Paterson HH, Schumm MA, Longstaff XR, Hughes EG, Tseng CH, Cheung DS, Yeh MW, Wu JX, Livhits MJ. Histopathologic And Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations. Endocr Pract. 2024 Dec 6:S1530-891X(24)00857-7. doi: 10.1016/j.eprac.2024.12.001. Epub ahead of print. PMID: 39647526.

Tags: BRAF V600E, Endocrinology, General Internal Medicine, molecular testing, Publications, RAS, recurrence, thyroid cancer

A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors

Mogar N, Zhang D, Heaney AP. A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors. Int J Mol Sci. 2025 Jun 19;26(12):5898.[...]

Metabolic Messengers: oestradiol

Hevener AL, Correa SM. Metabolic Messengers: oestradiol. Nat Metab. 2025 Jun;7(6):1114-1122. doi: 10.1038/s42255-025-01317-7. Epub 2025 Jun 24. PMID: 40562968.

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]